Skip to main content

UCB

UCB SA is a global biopharmaceutical enterprise specializing in the discovery, clinical development, and commercialization of innovative medicines for severe diseases. The company concentrates its research and commercial operations across two primary therapeutic focus areas: neurology and immunology. Its key commercial product portfolio includes biopharmaceutical therapeutics such as Bimzelx, Cimzia, Evenity, Vimpat, and Keppra, addressing conditions such as severe psoriasis, rheumatoid arthritis, postmenopausal osteoporosis, and epilepsy. Principal revenue drivers consist of global commercial sales of proprietary prescription pharmaceuticals, alongside strategic licensing agreements and research partnerships. UCB serves international end markets encompassing hospital networks, specialty care clinics, wholesale drug distributors, government health authorities, and patients across Europe, the Americas, and Asia-Pacific. The company holds a prominent market position in global immunology and central nervous system therapeutics as a major European biopharmaceutical manufacturer. Headquartered in Brussels, Belgium, UCB's common stock is publicly traded on the Euronext Brussels stock exchange under the ticker symbol UCB.

116 of the funds FundTelligence covers report a position in UCB.

Legal name
UCB SA
Sector
Health Care
Country
Belgium
Funds holding it
116
Exposure themes
Autoimmune diseases, Treatment, Women's Health

Funds holding UCB

Showing the 8 largest of 116 funds holding it.

Loading...